Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 7/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326142 | 0.90 | IL1B (0.44) | IL1BNLRP3CCNT1 | |
| SCHEMBL27182181 | 0.84 | NLRP3 (0.45) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL29326670 | 0.83 | NLRP3 (0.54) | IL1BNLRP3KCNH2TNFLIPC | |
| SCHEMBL29974966 | 0.79 | NLRP3 (0.49) | IL1BNLRP3KCNH2TNFSYK | |
| SCHEMBL27182188 | 0.78 | IL1B (0.56) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL29326831 | 0.78 | NLRP3 (0.51) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL29326829 | 0.78 | NLRP3 (0.51) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL29326138 | 0.78 | TRPV1 (0.44) | IL1BNLRP3KCNH2 | |
| SCHEMBL27182186 | 0.77 | NLRP3 (0.43) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL27182189 | 0.76 | NLRP3 (0.47) | IL1BNLRP3KCNH2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885NLRP3 1/4885KCNH2 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.